/term/ShortInterest/STU:SP4P Achieve Life Sciences (STU:SP4P) Short Interest
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » Short Interest

Achieve Life Sciences (STU:SP4P) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Achieve Life Sciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Achieve Life Sciences's Short Interest

For the Biotechnology subindustry, Achieve Life Sciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Short Interest falls into.


Achieve Life Sciences (STU:SP4P) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » Short Interest
Comparable Companies
BLUE OTLK ATOS GALT OBIO CAPR VERU YS PBYI OMER OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ACHV:USA SP4P:Germany
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Website
https://www.achievelifesciences.com
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (STU:SP4P) Headlines

No Headlines